Company: BGLC
Filing Date: 2025-11-07
Form Type: S-3
Source: 0001477932-25-007976
Chunk: 51

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-07
Form: S-3
Chunk 51
---
 filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. |

| (c) | Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. |

| II-3 |

EXHIBIT INDEX

| Exhibit No. 
 1.1*        
 3.1         |     | Description                                                                                                                                                                                                                                                                                                           
 Equity Distribution Agreement, dated November 7, 2025, between BioNexus Gene Lab Corp. and Maxim Group LLC.                                                                                                                                                                                                           
 Articles of Incorporation of BioNexus Gene Lab Corp. (Incorporated by reference to Exhibit 3.1 to the Registration Statement on Form S-1 (File No. 333-229399) filed with the SEC on January 29, 2019).                                                                                                               |
|:------------|:----|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3.2         |     | Amended and Restated Bylaws of BioNexus Gene Lab Corp (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the SEC on September 5, 2024).                                                                                                                                           |
| 3.3         |